Sabine Maier

Title: The Innovative Contributions of Sabine Maier

Introduction

Sabine Maier is a prominent inventor based in Lawrenceville, NJ (US). She has made significant contributions to the field of oncology, particularly in the treatment of lung cancer. With a total of 2 patents, her work focuses on innovative methods to enhance cancer treatment efficacy.

Latest Patents

Maier's latest patents include groundbreaking methods for treating non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). One patent details a method for treating NSCLC by administering a combination of platinum doublet chemotherapy followed by an anti-PD-1 antibody and an anti-CTLA-4 antibody. This approach aims to improve patient outcomes by optimizing the timing and combination of therapies. Another patent outlines a method for treating SCLC with a high tumor mutational burden (TMB) status, utilizing either monotherapy with an anti-PD-1 antibody or a combination therapy. This method also includes a process for identifying suitable patients based on their TMB status, which can be determined through genomic sequencing.

Career Highlights

Sabine Maier is currently associated with Bristol-Myers Squibb Company, where she continues to advance her research in cancer therapies. Her innovative approaches have the potential to significantly impact treatment protocols and patient care in oncology.

Collaborations

Maier collaborates with esteemed colleagues, including Prabhu Seshaiyer Bhagavatheeswaran and Nicholas Allan John Botwood. These partnerships enhance her research capabilities and contribute to the development of effective cancer treatments.

Conclusion

Sabine Maier's contributions to cancer treatment through her patents and collaborations highlight her role as a leading inventor in the field. Her innovative methods promise to improve the lives of many patients battling lung cancer.